TransMedics Net Worth

TransMedics Net Worth Breakdown

  TMDX
The net worth of TransMedics Group is the difference between its total assets and liabilities. TransMedics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of TransMedics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. TransMedics' net worth can be used as a measure of its financial health and stability which can help investors to decide if TransMedics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in TransMedics Group stock.

TransMedics Net Worth Analysis

TransMedics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including TransMedics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of TransMedics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform TransMedics' net worth analysis. One common approach is to calculate TransMedics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares TransMedics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing TransMedics' net worth. This approach calculates the present value of TransMedics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of TransMedics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate TransMedics' net worth. This involves comparing TransMedics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into TransMedics' net worth relative to its peers.

Enterprise Value

2.82 Billion

To determine if TransMedics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TransMedics' net worth research are outlined below:
TransMedics Group generated a negative expected return over the last 90 days
TransMedics Group has high historical volatility and very poor performance
The company reported the previous year's revenue of 241.62 M. Net Loss for the year was (25.03 M) with profit before overhead, payroll, taxes, and interest of 65.27 M.
TransMedics Group currently holds about 204.46 M in cash with (13.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.41.
Over 97.0% of the company shares are owned by institutional investors
Latest headline from gurufocus.com: TransMedics Group Inc Shares Up 5.2 percent on Nov 27
TransMedics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in TransMedics Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to TransMedics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know TransMedics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as TransMedics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TransMedics Group backward and forwards among themselves. TransMedics' institutional investor refers to the entity that pools money to purchase TransMedics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Eventide Asset Management, Llc2024-09-30
690.6 K
Allspring Global Investments Holdings, Llc2024-06-30
569 K
Mackenzie Investments2024-09-30
478.7 K
Fuller & Thaler Asset Management Inc2024-09-30
456.5 K
1832 Asset Management L.p2024-09-30
455.4 K
Bank Of New York Mellon Corp2024-06-30
420.7 K
Sandhill Capital Partners Llc2024-09-30
392.6 K
Fidelity International Ltd2024-06-30
376.8 K
Man Group Plc2024-09-30
345.3 K
Vanguard Group Inc2024-09-30
3.6 M
Blackrock Inc2024-06-30
2.6 M
Note, although TransMedics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow TransMedics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.92 B.

Market Cap

2.69 Billion

Project TransMedics' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.04)(0.04)
Return On Capital Employed(0.04)(0.05)
Return On Assets(0.04)(0.04)
Return On Equity(0.18)(0.17)
The company has Profit Margin (PM) of 0.08 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.
When accessing TransMedics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures TransMedics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TransMedics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in TransMedics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TransMedics Group. Check TransMedics' Beneish M Score to see the likelihood of TransMedics' management manipulating its earnings.

Evaluate TransMedics' management efficiency

TransMedics Group has return on total asset (ROA) of 0.0284 % which means that it generated a profit of $0.0284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1941 %, meaning that it created $0.1941 on every $100 dollars invested by stockholders. TransMedics' management efficiency ratios could be used to measure how well TransMedics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.04 in 2024. Return On Capital Employed is likely to drop to -0.05 in 2024. At this time, TransMedics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 226.3 M in 2024, whereas Intangible Assets are likely to drop slightly above 1.9 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 4.22  4.43 
Tangible Book Value Per Share 3.78  3.97 
Enterprise Value Over EBITDA(353.51)(335.83)
Price Book Value Ratio 18.71  19.64 
Enterprise Value Multiple(353.51)(335.83)
Price Fair Value 18.71  19.64 
Enterprise Value2.7 B2.8 B
Management at TransMedics Group focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue
7.7578
Revenue
401.1 M
Quarterly Revenue Growth
0.637
Revenue Per Share
12.157
Return On Equity
0.1941
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TransMedics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TransMedics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TransMedics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Basile Edward M few days ago
Disposition of 6750 shares by Basile Edward M of TransMedics at 28.12 subject to Rule 16b-3
 
Hassanein Waleed H over a month ago
Disposition of 1865 shares by Hassanein Waleed H of TransMedics at 152.3 subject to Rule 16b-3
 
Hassanein Waleed H over three months ago
Acquisition by Hassanein Waleed H of 8625 shares of TransMedics at 13.28 subject to Rule 16b-3
 
Hassanein Waleed H over three months ago
Disposition of 205 shares by Hassanein Waleed H of TransMedics at 171.86 subject to Rule 16b-3
 
Tobin James R over three months ago
Disposition of 7336 shares by Tobin James R of TransMedics at 159.96 subject to Rule 16b-3
 
Khayal Tamer I over three months ago
Disposition of 1458 shares by Khayal Tamer I of TransMedics at 38.46 subject to Rule 16b-3
 
Weill David over six months ago
Disposition of 1193 shares by Weill David of TransMedics at 141.65 subject to Rule 16b-3
 
Khayal Tamer I over six months ago
Disposition of 100 shares by Khayal Tamer I of TransMedics at 113.16 subject to Rule 16b-3
 
Hassanein Waleed H over six months ago
Disposition of 4000 shares by Hassanein Waleed H of TransMedics at 95.12 subject to Rule 16b-3
 
Khayal Tamer I over six months ago
Disposition of 8341 shares by Khayal Tamer I of TransMedics at 16.14 subject to Rule 16b-3
 
Khayal Tamer I over six months ago
Disposition of 2917 shares by Khayal Tamer I of TransMedics at 16.14 subject to Rule 16b-3
 
Stephen Gordon over six months ago
Disposition of 15000 shares by Stephen Gordon of TransMedics at 74.01 subject to Rule 16b-3

TransMedics Corporate Filings

F4
13th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10Q
29th of October 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
28th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
7th of October 2024
An amended filing to the original Schedule 13G
ViewVerify
TransMedics time-series forecasting models is one of many TransMedics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TransMedics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

TransMedics Earnings per Share Projection vs Actual

TransMedics Corporate Management

Miriam ProvostVice AffairsProfile
Mark AndersonSenior DevelopmentProfile
Susan GoodmanVice ResourcesProfile
John CareyVP OperationsProfile
Nick CorcoranSenior OperationsProfile
Tamer MDChief OfficerProfile

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.